March is a catalyst-rich month for biotech and drug stocks.
In Europe, Endocyte (ECYT - Get Report) and Merck (MRK) are expecting a decision on accelerated approval for their ovarian cancer therapy vintafolide following the CHMP meeting scheduled for March 17-20. The announcement decision will come no later than March 21.
Three significant FDA advisory committee meetings to look forward to later this month.
On March 26-27 the FDA's Molecular and Clinical Genetics Panel will review two non-invasive screening tests for colon cancer: Epigenomics' blood-based Epi proColon and Exact Sciences' (EXAS) stool-based Cologuard. Look for FDA briefing documents for Epigenomics on March 24 and Exact Sciences on March 25.
On March 31, the FDA's Anti-Infective Drugs Advisory Committee will review two new antibiotics: Cubist Pharmaceuticals' CBST tedizolid and Durata Therapeutics' (DRTX) dalbavancin. FDA briefing documents will be posted to the agency's web site on March 27.
On April 1, the Endocrinologic and Metabolic Drugs Advisory Committee will review MannKind's (MNKD) inhaled, rapid-acting insulin Afrezza. The Afrezza FDA panel counts as a March event because FDA briefing documents will be made available on March 28.
On the clinical side:
Top-line results from a phase II study of Insmed's (INSM) Arikace in lung disease caused by nontuberculous mycobacteria (NTM).
Top-line results from a phase II study of Endocyte and Merck's vintafolide in non-small lung cancer.
Prana Biotech (PRAN) will announce results from a phase II study of PBT2 in Alzheimer's disease.
10/14/15 - 11:47 AM EDT
05/19/15 - 04:42 PM EDT
05/19/15 - 12:48 PM EDT
05/18/15 - 08:06 AM EDT
05/05/15 - 02:43 PM EDT
02/12/16 - 21:00 PM EST
02/12/16 - 21:00 PM EST
02/12/16 - 08:46 AM EST
02/12/16 - 08:42 AM EST
02/11/16 - 08:44 AM EST
All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.
Trifecta Stocks analyzes over 4,000 equities weekly to find the elite 1% of stocks that pass rigorous quantitative, fundamental and technical tests.
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
Chris Versace, using sophisticated stock screening and fundamental research, identifies potentially explosive small and mid-cap stocks.
Master swing trader Alan Farley uses his sophisticated software screens to review thousands of stocks each day for you, to find just the handful that meet his demanding criteria.